High performance of integrase genotyping on diverse HIV-1 clades circulating in Cameroon: toward a successful transition to dolutegravir-based regimens in low and middle-income countries

•Integrase genotyping is highly effective at the WHO-threshold of ≥1000 copies/mL;•Assay performance increases with viremia, reaching 84% at ≥100.000copies/mL;•The assay has an acceptable performance even at low-level viremia ≥500copies/mL;•Assay performance decreases substantially with viremia...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diagnostic microbiology and infectious disease 2022-02, Vol.102 (2), p.115574-115574, Article 115574
Hauptverfasser:	Fokam, Joseph, Ngoufack Jagni Semengue, Ezechiel, Armenia, Daniele, Takou, Désiré, Dambaya, Béatrice, Teto, Georges, Chenwi, Collins Ambe, Nka, Alex Durand, Beloumou, Grâce Angong, Ndjeyep, Sandrine Claire Djupsa, Tchouaket, Michel Carlos Tommo, Fainguem, Nadine, Sosso, Samuel Martin, Colizzi, Vittorio, Perno, Carlo-Federico, Ndjolo, Alexis, Ceccherini-Silberstein, Francesca, Santoro, Maria Mercedes
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Aged, 80 and over Anti-HIV Agents - therapeutic use Cameroon Cameroon - epidemiology Child Child, Preschool Cross-Sectional Studies Developing Countries dolutegravir Female Genetic Variation Genotype Genotyping Techniques Heterocyclic Compounds, 3-Ring - therapeutic use HIV Infections - drug therapy HIV Integrase Inhibitors - pharmacology HIV Integrase Inhibitors - therapeutic use HIV-1 HIV-1 - drug effects HIV-1 - genetics Humans Integrase-genotyping Male Middle Aged Oxazines - pharmacology Oxazines - therapeutic use Piperazines - pharmacology Piperazines - therapeutic use Pyridones - pharmacology Pyridones - therapeutic use viral clades Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	•Integrase genotyping is highly effective at the WHO-threshold of ≥1000 copies/mL;•Assay performance increases with viremia, reaching 84% at ≥100.000copies/mL;•The assay has an acceptable performance even at low-level viremia ≥500copies/mL;•Assay performance decreases substantially with viremia
ISSN:	0732-8893 1879-0070
DOI:	10.1016/j.diagmicrobio.2021.115574